INTRODUCTION
Hypertension is the most common cardiovascular condition in the world and is the leading preventable cause of morbidity and mortality due to coronary heart disease, stroke, heart failure, and kidney failure. 1 In the urban adult populations of Asia, the prevalence, using the criterion of blood pressure (BP) ≥140/90 mmHg, varies between 15% and 35%, although it is lower in rural areas. [2] [3] [4] Despite the availability of a wide range of antihypertensive drugs, mild to moderate hypertension still remains poorly controlled. 5 Inadequate lowering of BP with antihypertensive therapy can be attributed to several factors, such as multiple pathophysiological mechanisms involved and the heterogeneity among patients, the failure of physicians to titrate or modify first-line therapy to reach the recommended target BP, and the lack of patient compliance. Combination therapy also has the advantage of achieving improved antihypertensive efficacy at low individual drug doses compared with those used in monotherapy and, therefore, has a lower incidence of adverse effects. 8 Valsartan, an angiotensin II receptor blocker (ARB), lowers BP mainly by blocking the effects of angiotensin II on vascular smooth muscle. 9 It also blocks the aldosterone-mediated retention of sodium and excretion of potassium in the distal tubule by preventing angiotensininitiated aldosterone release from the adrenal gland.
Hydrochlorothiazide (HCTZ), a thiazide diuretic, is thought to lower BP primarily by decreasing sodium resorption in the renal distal convoluted tubules. 10, 11 This sodium depletion causes a reflex increase in plasma renin activity, a subsequent increase in angiotensin, and in aldosterone secretion, and urinary retention of sodium accompanied by excretion of potassium. 
MATERIALS AND METHODS

Study Objectives
This multinational, open-label, observational, 
RESULTS
Baseline Characteristics
All 7567 patients who took at least one dose of valsartan/HCTZ SPC were included in the statistical analysis. Patient demographics and baseline characteristics are shown in showed moderate agreement for efficacy assessments between patients and physicians.
The global assessment for tolerability of valsartan/HCTZ SPC is summarized in Table 3 
Association Between Treatment Response and Age
A significant association between age and response was found at week 4; the response rates were 65.6% for those younger than 50 years and Missing values among the intent-to-treat (ITT) population were 269 (3.6%), 735 (9.7%), and 994 (13.1%) at week 4, week 12, and week 24, due to no blood pressure examinations. *Responders were defined as those patients with SBP <140 mmHg and/or DBP <90 mmHg, or a reduction of >10 mmHg in DBP and/or a reduction of >20 mmHg in SBP compared to baseline. †Blood pressure controlled was defined as SBP <140 mmHg and DBP <90 mmHg. DBP=diastolic blood pressure; SBP=systolic blood pressure. Table 4) . n=6671 instead of 7567 because 896 (11.8%) subjects in the intent-to-treat population had no assessment for tolerability either by themselves or by physicians. concluded that combination therapy was more effective in terms of response rate.
Safety of Valsartan/HCTZ SPC
In the current study, we noticed that the younger patients (<50 years old) showed more DBP reduction than older patients. However, a current study by Asmar and Oparil showed older patients (>65 years old) achieve a greater DBP reduction than younger patients. 23 Although the difference was only 1 mmHg, it was statistically significant. The correlation between age and BP reduction will require additional confirmation in future investigations, and the clinical interpretation should be further discussed.
Regardless, in the current study, females showed a significantly smaller DBP reduction than males at week 12 and week 24. However, the difference between males and females was only 1 mmHg, and the significance is marginal at week 24. In the Asmar and Oparil study, females also showed a 1 mmHg smaller DBP reduction than males, but this difference was not statistically significant. 23 Treatment with valsartan/HCTZ SPC was well tolerated for most patients, and almost all patients rated the tolerability with good or better.
Almost all patients also rated the combination as efficacious, but because mild hypertension is symptomless, this subjective judgment reflected whether the patient's BP had reached a value the patient thought acceptable, rather than whether actual control had been achieved.
Choice of antihypertensive drugs depends on cost, anticipated side effects, and the physician's familiarity with the drug. Clinical trials have shown valsartan/HCTZ to be more effective than either drug alone and to have an adverse effect profile similar to that of placebo. 19 The current study is the largest study to date, and includes Whether first line combination therapy has an effect on the number of therapies required in the future in order to obtain BP control will also be in the area of interest.
One limitation of the study was that there was a lack of data on patients who changed their nonstudy antihypertensive drug(s) during the course of the study. Another is that there was insufficient data necessary to perform subgroup analyses. 
CONCLUSION
